Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 150

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 150
---
 external director under the Companies Law subject to the ratification of his/her appointment at a general meeting of     
 our shareholders to be held following the completion of this offering.                                                               |

Dr. Ehud Geller, Chairman of the Board of Directors

Dr.
Ehud Geller has served as the Chairman of our Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner
of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical
Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President
and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli
Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical
Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel
Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve
on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry
and his significant leadership experience. His experience leading the Company’s management and the depth of his knowledge of our
business enable him to provide valuable leadership on complex business matters that we face on an ongoing basis. Dr. Geller will devote
approximately 50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed
by Medica Venture Partners.

Dr. Eli Hazum, Chief Executive Officer

Dr. Eli Hazum has served
as our Chief Executive Officer since October 2021. He has been a partner and Chief Security Officer of Medica Venture Partners since
1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic
Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received
his Ph.D. degree in the field of hormone biochemistry from the Weizmann Institute of Science, B